替罗非班在急性缺血性卒中患者中的应用  

Application of tirofiban in patients with acute ischemic stroke

作　　者：江莉 梁志刚[2,3] 张振 Jiang Li;Liang Zhigang;Zhang Zhen(The Second Clinical Medical College of Binzhou Medical University,Yantai 264003,China;Department of Neurology,Yantai Yuhuangding Hospital Affiliated to Qingdao University,Yantai 264000,China;Shandong Provincial Key Laboratory of Neuroimmune Interaction and Regulation,Yantai 264000,China)

机构地区：[1]滨州医学院第二临床医学院,烟台264003 [2]青岛大学附属烟台毓璜顶医院神经内科,烟台264000 [3]山东省神经免疫互作与调控重点实验室,烟台264000

出　　处：《国际脑血管病杂志》2024年第9期687-693,共7页International Journal of Cerebrovascular Diseases

基　　金：烟台市科技发展计划(2018SFGY092,2021YD033)。

摘　　要：替罗非班是血小板糖蛋白Ⅱb/Ⅲa受体拮抗药,通过抑制血小板聚集过程的最后共同通路阻止血栓形成。目前,替罗非班应用于急性缺血性卒中患者的相关临床研究日益增多,但其安全性和有效性仍存在着争议。文章就替罗非班在急性缺血性卒中患者中的应用进行了综述。Tirofiban is a platelet glycoproteinⅡb/Ⅲa receptor antagonist that prevents thrombosis by inhibiting the final common pathway of platelet aggregation.At present,there are increasing clinical studies on the application of tirofiban in patients with acute ischemic stroke,but its safety and efficacy are still controversial.This article reviews the application of tirofiban in patients with acute ischemic stroke.

关 键 词：缺血性卒中 替罗非班 抗血小板聚集药 血栓溶解疗法 血管内手术 血栓切除术 治疗结果 

分 类 号：R74[医药卫生—神经病学与精神病学]